ESMO Asia Congress 2024
Sacituzumab govitecan failed to improve overall survival in pre-treated urothelial carcinoma
Despite being active in this disease setting, the antibody-drug conjugate was associated to high rates of neutropenic complications
Targeting claudins in pancreatic adenocarcinoma is promising, early-phase findings suggest
Study confirms favourable safety profiles and encouraging efficacy of an anti-claudin 18.2 antibody-drug conjugate
Three new Pan-Asian-adapted guidelines at ESMO Asia Congress
The latest tumour types covered in the ESMO PAGAs are biliary tract cancers, oncogene-addicted metastatic non-small cell lung cancer and epithelial ovarian cancer
Preventing the rise in obesity-related cancers in Asia
Long-term multisectoral preventive actions that take into account local requirements are needed
Immunotherapy combinations consolidate their place in the first-line treatment of unresectable hepatocellular carcinoma
Promising new data are presented for nivolumab plus ipilimumab and the single tremelimumab regular interval durvalumab regimen in Asian patients and those with impaired liver function
Studies show two promising new immune-related targets in cancer
Agents targeting B7-H3 and CEACAM6 pass their initial clinical tests, according to results from first-in-human trials
Short durvalumab infusions appear to be safe for the first-line treatment of advanced biliary tract cancer
Early results from a phase III trial support 30-minutes infusions of immunotherapy with some advantages for patients
Two oral immune checkpoint inhibitors show preliminary efficacy and manageable safety in early trials
Promising results support the further development of new small-molecule PD-L1 inhibitors with favourable benefit–risk profiles and improved ease of use compared with antibodies